Mtx (Methotrexate Disodium)

Methotrexate works by inhibiting the enzyme dihydrofolate reductase, which is essential for converting folate into its active forms needed for DNA, RNA and protein synthesis. By blocking this pathway, the drug reduces the proliferation of rapidly dividing cells, such as activated immune cells in autoimmune disease and malignant cells in certain cancers, thereby dampening inflammation and tumor growth.

The specific dose of Mtx is individualized and set by the prescribing healthcare professional based on the patient’s condition, weight, renal function, and treatment goals. Dosage may vary widely between indications such as low‑dose weekly regimens for rheumatoid arthritis and higher, more frequent dosing for oncologic protocols. Patients should follow the prescriber’s instructions precisely.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant. Women of child‑bearing potential must use effective contraception while on therapy.

To request Mtx, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the initial request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The primary alternative to methotrexate in rheumatoid arthritis is leflunomide or biologic agents such as TNF‑alpha inhibitors. Methotrexate is generally less expensive and has a long safety record, but it may require more frequent monitoring for liver and bone‑marrow effects. Biologics often have a different side‑effect profile, focusing on infection risk, and are usually reserved for patients who do not respond adequately to methotrexate.

Mtx oral tablets should be stored at ambient temperature, ideally below 25 °C (77 °F). Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed. Do not refrigerate or freeze the product, as temperature extremes can affect tablet integrity.

Mtx is administered orally as a tablet that should be swallowed whole with a full glass of water. It can be taken with or without food, although some patients prefer taking it with food to reduce gastrointestinal upset. Dosing frequency (often weekly for rheumatic diseases) is determined by the prescriber, and patients should adhere strictly to the prescribed schedule.

The most serious adverse effects of methotrexate include severe liver toxicity (which can progress to hepatitis or fibrosis), pulmonary fibrosis (a potentially irreversible lung condition), and profound bone‑marrow suppression leading to pancytopenia. Patients should be educated to report symptoms such as persistent fatigue, jaundice, shortness of breath, or unusual bruising promptly to their healthcare provider.

Methotrexate should be avoided in individuals who are pregnant, planning to become pregnant, or are breastfeeding. It is also contraindicated in patients with severe hepatic impairment, significant renal dysfunction, or uncontrolled infections. Patients with known hypersensitivity to methotrexate or any of its excipients should not receive the medication, and clinicians must assess each case before initiating therapy.